camptothecin has been researched along with oligonucleotides in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.29) | 18.2507 |
| 2000's | 22 (62.86) | 29.6817 |
| 2010's | 8 (22.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kohlhagen, G; Kohn, KW; Leteurtre, F; Pommier, Y; Wall, ME; Wani, MC | 1 |
| Calderwood, SK; Coleman, CN; Price, BD; Tishler, RB | 1 |
| Chourpa, I; Manfait, M; Millot, JM; Pommier, Y; Riou, JF | 1 |
| Hecht, SM; Johnson, RK; Kingsbury, WD; Short, GF; Wang, X | 1 |
| Bjornsti, MA; Essigmann, JM; Fertala, J; Park, HJ; Pommier, Y; Pourquier, P; Ueng, LM; Wang, D | 1 |
| Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Cho, YS; Cho-Chung, YS | 1 |
| Angenault, S; Arimondo, PB; Bailly, C; Boutorine, A; Garestier, T; Halby, L; Hélène, C; Monneret, C; Schmidt, F; Sun, JS | 1 |
| Benedetti, P; Bruselles, A; Chillemi, G; Desideri, A; Falconi, M; Fiorani, P | 1 |
| Antony, S; Cushman, M; Jayaraman, M; Kohlhagen, G; Kohn, KW; Laco, G; Pommier, Y | 1 |
| Bellucci, MC; Dallavalle, S; Fraternali, F; Mazzini, S; Mondelli, R | 1 |
| Becerra, CR; Frenkel, EP; Gaynor, RB; Guo, J; Verma, UN | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Cui, Y; Li, WH; Zhu, JR | 1 |
| Ferrara, L; Kmiec, EB | 1 |
| Arimondo, PB; Bailly, C; Boutorine, A; Garestier, T; Halby, L; Hecht, SM; Laco, GS; Pez, D; Pommier, Y; Schmitt, P; Sun, JS; Thomas, CJ | 1 |
| Cheng, YC; Park, SY | 1 |
| Arimondo, PB; Bailly, C; Baldeyrou, B; Giovannangeli, C; Guianvarc'h, D; Halby, L; Hecht, SM; Lansiaux, A; Mahieu, C; Oussedik, K; Thomas, CJ | 1 |
| Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S | 1 |
| Barrows, LR; Marshall, KM; Pond, CD | 1 |
| Grosse, F; Hartung, S; Søe, K | 1 |
| Andersen, AH; Andersen, FF; Frøhlich, RF; Hede, MS; Knudsen, BR; Krüger, D; Petersen, RL | 1 |
| Li, T; Li, X; Liu, X; Tao Ng, MT; Wang, Y | 1 |
| Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Asakura, T; Kobayashi, S; Kumai, T; Matsumoto, N; Nakano, H; Nakaya, S; Ohtsubo, T; Sekine, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Carver, M; Punchihewa, C; Yang, D | 1 |
| Aladag, N; Aydinlik, S; Ozkan-Ariksoysal, D; Ozsoz, M; Topkaya, SN | 1 |
| Bohr, VA; Carrier, F; Devulapalli, C; Fu, H; Indig, FE; Karmakar, P; Rybanska, I | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Chan, E; de La Bourdonnaye, G; Heiskala, M; Hwang, J; Kwak, EL; Mita, M | 1 |
| Burris, HA; Chen, L; Goldstein, D; Hsu, CP; Hurwitz, H; Kotasek, D; Schwartzberg, LS; Stephenson, J; Tebbutt, N; Warner, DJ | 1 |
| Abdullah, S; Abi-Jaoudeh, N; Anderson, V; Duffy, AG; Figg, WD; Fioravanti, S; Greten, TF; Lee, S; Levy, E; MacLeod, AR; Makarova-Rusher, OV; Peer, CJ; Raffeld, M; Rahma, OE; Revenko, AS; Steinberg, SM; Tomita, Y; Trepel, JB; Ulahannan, SV; Walker, M; Wood, BJ | 1 |
| Qing, L; Qing, W | 1 |
1 review(s) available for camptothecin and oligonucleotides
| Article | Year |
|---|---|
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
3 trial(s) available for camptothecin and oligonucleotides
| Article | Year |
|---|---|
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotides; Toll-Like Receptor 9 | 2015 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Panitumumab; Young Adult | 2015 |
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Eukaryotic Initiation Factor-4E; Female; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides; RNA, Messenger | 2016 |
31 other study(ies) available for camptothecin and oligonucleotides
| Article | Year |
|---|---|
Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Topics: Alkylation; Base Sequence; Camptothecin; DNA; DNA Damage; DNA Topoisomerases, Type I; Drug Design; Molecular Sequence Data; Nucleic Acid Hybridization; Oligonucleotides; Sequence Analysis, DNA; Substrate Specificity; Topoisomerase I Inhibitors | 1995 |
Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents.
Topics: 3T3 Cells; Animals; Antibodies; Antineoplastic Agents; Base Sequence; Camptothecin; Dactinomycin; DNA; DNA Damage; Electrophoresis; Gene Expression Regulation; Hydrogen Peroxide; Mice; Molecular Sequence Data; Oligonucleotides; Protein Binding; Time Factors; Tumor Suppressor Protein p53 | 1993 |
Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Topics: Camptothecin; DNA Topoisomerases, Type I; DNA, Viral; Hydrolysis; Irinotecan; Kinetics; Lactones; Oligonucleotides; Simian virus 40; Spectrometry, Fluorescence; Topoisomerase I Inhibitors | 1998 |
Effects of camptothecin analogues on DNA transformations mediated by calf thymus and human DNA topoisomerases I.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cattle; Chromatography, High Pressure Liquid; DNA Topoisomerases, Type I; Humans; Molecular Sequence Data; Nucleic Acid Hybridization; Oligonucleotides | 1998 |
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine.
Topics: Camptothecin; Cytosine; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA-Binding Proteins; Guanosine; Humans; Kinetics; Molecular Structure; Mutation; Oligonucleotides; Oxidative Stress | 1999 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blotting, Western; Camptothecin; Carrier Proteins; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Cyclic AMP-Dependent Protein Kinases; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Humans; Male; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides, Antisense; Prostatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Up-Regulation | 2003 |
Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.
Topics: Base Sequence; Binding Sites; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Molecular Sequence Data; Nucleic Acid Conformation; Oligonucleotides | 2003 |
Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
Topics: Alanine; Binding Sites; Camptothecin; Catalysis; Cell Survival; DNA; DNA Topoisomerases, Type I; Drug Resistance; Enzyme Inhibitors; Humans; Ions; Kinetics; Models, Molecular; Mutation; Oligonucleotides; Plasmids; Proline; Protein Binding; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Time Factors; Tyrosine | 2003 |
Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Topics: Animals; Camptothecin; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Indenes; Isoquinolines; Oligonucleotides; Substrate Specificity; Topoisomerase I Inhibitors; Vaccinia | 2003 |
Mode of binding of camptothecins to double helix oligonucleotides.
Topics: Camptothecin; Computer Simulation; Isomerism; Models, Molecular; Nucleic Acid Conformation; Oligonucleotides | 2004 |
Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.
Topics: Agar; Animals; Antineoplastic Agents, Phytogenic; Baculoviral IAP Repeat-Containing 3 Protein; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Genes, Reporter; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Neoplasm Transplantation; NF-kappa B; Oligonucleotides; Proteins; RNA; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Ubiquitin-Protein Ligases | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
[Methylated oligonucleotide inhibiting expression of human MRP2 and reversing multidrug resistance in hepatocellular carcinoma Cell HepG2].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboplatin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oligonucleotides; RNA, Messenger; Transfection | 2004 |
Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination.
Topics: Androstadienes; Antineoplastic Agents, Phytogenic; Base Sequence; Benzaldehydes; Caffeine; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Green Fluorescent Proteins; Humans; Luminescent Proteins; Molecular Sequence Data; Oligonucleotides; Recombination, Genetic; Wortmannin | 2004 |
Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
Topics: Amino Acid Substitution; Base Sequence; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Stability; Humans; Molecular Sequence Data; Nucleic Acid Conformation; Nucleic Acid Heteroduplexes; Oligonucleotides; Point Mutation; Structure-Activity Relationship | 2005 |
Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.
Topics: Adenosine Triphosphate; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; NAD; Oligonucleotides; Peptide Fragments; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Recombinant Proteins; Topoisomerase I Inhibitors | 2005 |
Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cells, Cultured; DNA; DNA Topoisomerases, Type I; Fireflies; Gene Expression; Genes, Reporter; Humans; Luciferases; Molecular Sequence Data; Oligonucleotides; Tumor Cells, Cultured | 2006 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Islands; Dendritic Cells; Disease Models, Animal; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Mice; Mice, Inbred BALB C; Oligonucleotides | 2006 |
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Synergism; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasms; Oligonucleotides; Peptide Library; Peptides; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2006 |
Human topoisomerase I forms double cleavage complexes on natural DNA.
Topics: Camptothecin; Catalysis; Chromatin; Dimerization; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; HeLa Cells; Humans; Nucleic Acid Conformation; Oligonucleotides; Protein Binding; Protein Structure, Tertiary; Recombinant Proteins | 2006 |
Resolution of Holliday junction substrates by human topoisomerase I.
Topics: Base Sequence; Binding Sites; Camptothecin; Catalysis; Cross-Linking Reagents; Dimerization; DNA; DNA Topoisomerases, Type I; DNA, Cruciform; Humans; Molecular Sequence Data; Oligonucleotides; Protein Conformation; Protein Structure, Tertiary; Substrate Specificity | 2007 |
Dumbbell-shaped circular oligonucleotides as inhibitors of human topoisomerase I.
Topics: Anions; Base Pair Mismatch; Base Sequence; Binding Sites; Camptothecin; DNA Topoisomerases, Type I; DNA, Superhelical; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Nucleic Acid Conformation; Oligonucleotides | 2007 |
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; DNA Probes; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Oligonucleotides; Tumor Suppressor Protein p53 | 2007 |
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Microscopy, Fluorescence; Oligonucleotides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tumor Suppressor Protein p53 | 2007 |
DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.
Topics: Base Sequence; Camptothecin; DNA Cleavage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Hypoxia-Inducible Factor 1; Oligonucleotides; Recombinant Proteins; Response Elements; Topoisomerase I Inhibitors | 2009 |
Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.
Topics: Adsorption; Animals; Antineoplastic Agents; Biosensing Techniques; Camptothecin; DNA; Electrochemistry; Electrodes; Fishes; Graphite; High-Throughput Screening Assays; Irinotecan; Male; Oligonucleotides; Oxidation-Reduction; Sensitivity and Specificity; Spermatozoa; Surface Properties | 2010 |
Nucleolin inhibits G4 oligonucleotide unwinding by Werner helicase.
Topics: Camptothecin; Cell Line; Cell Nucleolus; Exodeoxyribonucleases; G-Quadruplexes; Humans; Immunoprecipitation; Nucleolin; Oligonucleotides; Phosphoproteins; Protein Binding; Protein Interaction Mapping; Protein Structure, Tertiary; Protein Transport; Recombinant Fusion Proteins; RecQ Helicases; RNA-Binding Proteins; Substrate Specificity; Werner Syndrome Helicase | 2012 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Hypoxia inducible factor 1 inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Digoxin; Flavonoids; Humans; Hypoxia-Inducible Factor 1; Mustard Compounds; Neoplasms; Oligonucleotides; Phenylpropionates; Polyethylene Glycols; Topotecan | 2019 |